Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 10 selected

Guidance programme

Showing 101 to 150 of 554

TitleReference numberPublishedLast updated
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Head injury: assessment and early managementNG232
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Diabetes (type 1 and type 2) in children and young people: diagnosis and managementNG18
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Hypertension in pregnancy: diagnosis and managementNG133
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Hip fracture: managementCG124
Upadacitinib for treating moderately to severely active ulcerative colitisTA856
Thyroid cancer: assessment and managementNG230
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Cabozantinib for previously treated advanced hepatocellular carcinomaTA849
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850

Results per page

  1. 10
  2. 25
  3. 50
  4. All